Restricted accessReview articleFirst published online 2025-12
Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin With Concomitant Piperacillin-Tazobactam Versus Other Beta-Lactams: A Systematic Review and Meta-Analysis
Objectives: To explore whether vancomycin (VAN) plus piperacillin-tazobactam (PTZ) was associated with an increased risk of acute kidney injury (AKI) compared with VAN plus other beta-lactams (BLs) or monotherapy in critically ill patients, where the evidence remains controversial. Data sources: PubMed, Cochrane, Web of Science, and Embase were searched from inception to June 2024. Study selection: Studies comparing the risk of AKI with one group receiving VAN+PTZ, and other groups receiving VAN plus other BLs, or monotherapy in critically ill. Data synthesis: This analysis included 20 articles with 28 243 participants. The majority of included studies were retrospective (95%, 19/20) and had moderate risks of bias (80.0%, 16/20). The results indicated VAN+PTZ was associated with a significantly higher risk of AKI compared with VAN plus other BLs (OR = 1.66, 95% CI = 1.42-1.94, P < 0.001). Subgroup analyses showed that compared with adults, children were associated with a higher risk of AKI when receiving VAN+PTZ (OR = 3.16 vs 1.59). Also, VAN+PTZ was associated with a significantly higher risk of severe stage 2 to 3 AKI than VAN plus other BLs (OR = 1.63, 95% CI = 1.28-2.06, P < 0.001). No significant difference was identified in mortality, dialysis, time to AKI, and length of stay between patients receiving VAN plus PTZ and other combinations. Conclusions: In critically ill, VAN plus PTZ was associated with an increased risk of AKI and severe stage 2 to 3 AKI compared with VAN plus other BLs, especially in children. However, more high-quality multicenter, prospective cohort studies, and randomized controlled studies are needed.
GoodmanKECosgroveSEPinelesL, et al. Significant regional differences in antibiotic use across 576 US hospitals and 11 701 326 adult admissions, 2016-2017. Clin Infect Dis. 2021;73(2):213-222. doi:10.1093/cid/ciaa570
2.
CôtéJMDesjardinsMMurrayPT.Does vancomycin-piperacillin-tazobactam cause pseudo-AKI, true nephrotoxicity, or both?Chest. 2023;164(2):273-274. doi:10.1016/j.chest.2023.05.009
3.
BellosIKarageorgiouVPergialiotisVPerreaDN.Acute kidney injury following the concurrent administration of antipseudomonal β-lactams and vancomycin: a network meta-analysis. Clin Microbiol Infect. 2020;26(6):696-705. doi:10.1016/j.cmi.2020.03.019
4.
ChenAYDengCYCalvachi-PrietoP, et al. A large-scale multicenter retrospective study on nephrotoxicity associated with empiric broad-spectrum antibiotics in critically ill patients. Chest. 2023;164(2):355-368. doi:10.1016/j.chest.2023.03.046
5.
CôtéJMKane-GillSLMurrayPT.A ray of hope in the discord: is adding piperacillin-tazobactam to vancomycin truly more nephrotoxic?Intensive Care Med. 2022;48(9):1208-1210. doi:10.1007/s00134-022-06861-4
6.
QianETCaseyJDWrightA, et al. Cefepime vs piperacillin-tazobactam in adults hospitalized with acute infection: the ACORN randomized clinical trial. JAMA. 2023;330(16):1557-1567. doi:10.1001/jama.2023.20583
7.
MianoTAHennessySYangW, et al. Association of vancomycin plus piperacillin-tazobactam with early changes in creatinine versus cystatin C in critically ill adults: a prospective cohort study. Intensive Care Med. 2022;48(9):1144-1155. doi:10.1007/s00134-022-06811-0
8.
WenSWangCHuoX, et al. JBP485 attenuates vancomycin-induced nephrotoxicity by regulating the expressions of organic anion transporter (Oat) 1, Oat3, organic cation transporter 2 (Oct2), multidrug resistance-associated protein 2 (Mrp2) and P-glycoprotein (P-gp) in rats. Toxicol Lett. 2018;295:195-204. doi:10.1016/j.toxlet.2018.06.1220
9.
WenSWangCDuanY, et al. OAT1 and OAT3 also mediate the drug-drug interaction between piperacillin and tazobactam. Int J Pharm. 2018;537(1-2):172-182. doi:10.1016/j.ijpharm.2017.12.037
10.
VallonVEralySARaoSR, et al. A role for the organic anion transporter OAT3 in renal creatinine secretion in mice. Am J Physiol Renal Physiol. 2012;302(10):F1293-F1299. doi:10.1152/ajprenal.00013.2012
11.
Kane-GillSLOstermannMShiJJoyceELKellumJA.Evaluating renal stress using pharmacokinetic urinary biomarker data in critically ill patients receiving vancomycin and/or piperacillin-tazobactam: a secondary analysis of the multicenter sapphire study. Drug Saf. 2019;42(10):1149-1155. doi:10.1007/s40264-019-00846-x
12.
HuttonBSalantiGCaldwellDM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777-784. doi:10.7326/M14-2385
MehtaRLKellumJAShahSV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11(2):R31. doi:10.1186/cc5713
16.
BellomoRRoncoCKellumJAMehtaRLPalevskyP; Acute Dialysis Quality Initiative workgroup. Acute renal failure–definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004;8(4):R204-R212. doi:10.1186/cc2872
17.
KhwajaA.KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120(4):c179-c184. doi:10.1159/000339789
18.
LuoDWanXLiuJTongT.Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res. 2018;27(6):1785-1805. doi:10.1177/0962280216669183
19.
WanXWangWLiuJTongT.Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135. doi:10.1186/1471-2288-14-135
20.
ElliottBPTangMMMaddenJA, et al. A retrospective cohort study assessing acute kidney injury and renal recovery among septic patients empirically treated with vancomycin piperacillin-tazobactam versus vancomycin cefepime. Intern Emerg Med. 2022;17(1):91-99. doi:10.1007/s11739-021-02772-2
21.
HammondDASmithMNPainterJTMeenaNKLusardiK.Comparative incidence of acute kidney injury in critically ill patients receiving vancomycin with concomitant piperacillin-tazobactam or cefepime: a retrospective cohort study. Pharmacotherapy. 2016;36(5):463-471. doi:10.1002/phar.1738
22.
O’CallaghanKHayKLavanaJMcNamaraJF.Acute kidney injury with combination vancomycin and piperacillin-tazobactam therapy in the ICU: a retrospective cohort study. Int J Antimicrob Agents. 2020;56(1):106010. doi:10.1016/j.ijantimicag.2020.106010
23.
BuckleyMSHartsockNCBerryAJ, et al. Comparison of acute kidney injury risk associated with vancomycin and concomitant piperacillin/tazobactam or cefepime in the intensive care unit. J Crit Care. 2018;48:32-38. doi:10.1016/j.jcrc.2018.08.007
24.
BuckleyMSKomerdeljIAD’AlessioPA, et al. Vancomycin with concomitant piperacillin/tazobactam vs. cefepime or meropenem associated acute kidney injury in the critically ill: a multicenter propensity score-matched study. J Crit Care. 2022;67:134-140. doi:10.1016/j.jcrc.2021.10.018
25.
AlmutairiMSAlnezaryFSChestnuttJMcAllisterMAlmohammedOAAlhifanyAA.Acute kidney injury associated with piperacillin-tazobactam versus other antibiotics combined with vancomycin in critically ill patients: a retrospective cohort study. Saudi Pharm J. 2023;31(12):101844. doi:10.1016/j.jsps.2023.101844
26.
BlevinsAMLashinskyJNMcCammonCKollefMMicekSJuangP.Incidence of acute kidney injury in critically ill patients receiving vancomycin with concomitant piperacillin-tazobactam, cefepime, or meropenem. Antimicrob Agents Chemother. 2019;63(5):e02658-18. doi:10.1128/AAC.02658-18
27.
BartlettJWGillonJHaleJJimenez-TruqueNBanerjeeR.Incidence of acute kidney injury among infants in the neonatal intensive care unit receiving vancomycin with either piperacillin/tazobactam or cefepime. J Pediatr Pharmacol Ther. 2020;25(6):521-527. doi:10.5863/1551-6776-25.6.521
28.
HolsenMRMeaneyCJHassingerABFuscoNM.Increased risk of acute kidney injury in critically ill children treated with vancomycin and piperacillin/tazobactam. Pediatr Crit Care Med. 2017;18(12):e585-e591. doi:10.1097/PCC.0000000000001335
29.
HundeshagenGHerndonDNCapekKD, et al. Co-administration of vancomycin and piperacillin-tazobactam is associated with increased renal dysfunction in adult and pediatric burn patients. Crit Care. 2017;21(1):318. doi:10.1186/s13054-017-1899-3
30.
GaoXLiJLiZP.Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized children with or without concomitant piperacillin-tazobactam. Fudan Univ J Med Sci. 2015;42(6):743. doi:10.3969/j.issn.1672-8467.2015.06.009
31.
JoyceELKane-GillSLPriyankaPFuhrmanDYKellumJA.Piperacillin/tazobactam and antibiotic-associated acute kidney injury in critically ill children. J Am Soc Nephrol. 2019;30(11):2243-2251. doi:10.1681/ASN.2018121223
32.
KangSParkJYuYMParkMSHanEChangMJ.Comparison of acute kidney injury and clinical prognosis of vancomycin monotherapy and combination therapy with beta-lactams in the intensive care unit. PLoS ONE. 2019;14(6):e0217908. doi:10.1371/journal.pone.0217908
33.
MolinaKCBarlettaJFHallSTYazdaniCHuangV.The risk of acute kidney injury in critically ill patients receiving concomitant vancomycin with piperacillin-tazobactam or cefepime. J Intensive Care Med. 2020;35(12):1434-1438. doi:10.1177/0885066619828290
34.
PipkinTPopeSKillianAGreenSAlbrechtBNugentK.Nephrotoxic risk associated with combination therapy of vancomycin and piperacillin-tazobactam in critically ill patients with chronic kidney disease. J Intensive Care Med. 2024;39(9):860-865. doi:10.1177/08850666241234577
35.
SchreierDJKashaniKBSakhujaA, et al. Incidence of acute kidney injury among critically ill patients with brief empiric use of antipseudomonal β-lactams with vancomycin. Clin Infect Dis. 2019;68(9):1456-1462. doi:10.1093/cid/ciy724
36.
SheikhSBaigMASharafatMA, et al. Concerning nephrotoxicity of top guns: concomitant piperacillin-tazobactam and vancomycin with vancomycin alone during treatment of critically ill patients. Eurasian J Emerg Med. 2020;19(1):1-5. doi:10.4274/eajem.galenos.2019.04934
37.
InageSNakamuraSIsoeYet al. Acute kidney injury in non-intensive care and intensive care patients treated with vancomycin and piperacillin-tazobactam. J Nippon Med Sch. 2020;87(2):66-72. doi:10.1272/jnms.JNMS.2020_87-203
38.
AlshehriAMAlzahraniMYAbujamalMA, et al. Comparative risk of acute kidney injury following concurrent administration of vancomycin with piperacillin/tazobactam or meropenem: a systematic review and meta-analysis of observational studies. Antibiotics (Basel). 2022;11(4):526. doi:10.3390/antibiotics11040526
39.
KalligerosMKarageorgosSAShehadehFZacharioudakisIMMylonakisE.The association of acute kidney injury with the concomitant use of vancomycin and piperacillin/tazobactam in children: a systematic review and meta-analysis. Antimicrob Agents Chemother. 2019;63(12):e01572-19. doi:10.1128/AAC.01572-19
40.
LutherMKTimbrookTTCaffreyARDosaDLodiseTPLaPlanteKL.Vancomycin plus piperacillin-tazobactam and acute kidney injury in adults: a systematic review and meta-analysis. Crit Care Med. 2018;46(1):12-20. doi:10.1097/CCM.0000000000002769
41.
HammondDASmithMNLiCHayesSMLusardiKBookstaverPB.Systematic review and meta-analysis of acute kidney injury associated with concomitant vancomycin and piperacillin/tazobactam. Clin Infect Dis. 2017;64(5):666-674. doi:10.1093/cid/ciw811
42.
BlearsEEMorrisJPoppDLeeJONorburyWB.Kidney injury in critically ill patients treated with vancomycin and zosyn or an alternative: a systematic review and meta-analysis. Surg Infect (Larchmt). 2022;23(6):516-524. doi:10.1089/sur.2022.128
43.
AvedissianSNPaisGMLiuJRhodesNJScheetzMH.Piperacillin-tazobactam added to vancomycin increases risk for acute kidney injury: fact or fiction?Clin Infect Dis. 2020;71(2):426-432. doi:10.1093/cid/ciz1189
44.
DongJLiuYLiLDingYQianJJiaoZ.Interactions between meropenem and renal drug transporters. Curr Drug Metab. 2022;23(5):423-431. doi:10.2174/1389200223666220428081109
45.
ZhangMHuangLZhuY, et al. Epidemiology of vancomycin in combination with piperacillin/tazobactam-associated acute kidney injury in children: a systematic review and meta-analysis. Ann Pharmacother. 2024;58(10):1034-1044. doi:10.1177/10600280231220379
46.
AbdelmessihEPatelNVekariaJ, et al. Vancomycin area under the curve versus trough only guided dosing and the risk of acute kidney injury: systematic review and meta-analysis. Pharmacotherapy. 2022;42(9):741-753. doi:10.1002/phar.2722
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
